TRAVERE THERAPEUTICS INC's ticker is TVTX and the CUSIP is 89422G107. A total of 171 filers reported holding TRAVERE THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.73 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $160,750 | -48.5% | 17,981 | -11.5% | 0.10% | -47.0% |
| Q2 2023 | $311,946 | -16.8% | 20,309 | +21.8% | 0.18% | -10.2% |
| Q1 2023 | $374,998 | +8.9% | 16,674 | +1.8% | 0.21% | +14.4% |
| Q4 2022 | $344,492 | +39.5% | 16,381 | +63.5% | 0.18% | +83.7% |
| Q3 2022 | $247,000 | +3.3% | 10,019 | +1.5% | 0.10% | +10.1% |
| Q2 2022 | $239,000 | -34.3% | 9,875 | -30.0% | 0.09% | -45.4% |
| Q1 2022 | $364,000 | -16.9% | 14,116 | 0.0% | 0.16% | -1.2% |
| Q4 2021 | $438,000 | -38.8% | 14,116 | -52.2% | 0.16% | -47.6% |
| Q3 2021 | $716,000 | +52.0% | 29,543 | -8.4% | 0.32% | +62.4% |
| Q2 2021 | $471,000 | -21.1% | 32,254 | +34.9% | 0.19% | -23.0% |
| Q1 2021 | $597,000 | – | 23,907 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Lynx1 Capital Management LP | 411,680 | $10,609,000 | 9.85% |
| VR Adviser, LLC | 1,994,997 | $51,411,000 | 8.33% |
| Kynam Capital Management, LP | 870,918 | $22,444,000 | 7.28% |
| GREAT POINT PARTNERS LLC | 1,010,000 | $26,028,000 | 6.29% |
| Deep Track Capital, LP | 3,134,503 | $80,776,000 | 5.18% |
| RA Capital Management | 4,922,941 | $126,864,000 | 2.77% |
| ARMISTICE CAPITAL, LLC | 4,958,000 | $127,768,000 | 2.47% |
| MPM BioImpact LLC | 277,950 | $7,163,000 | 1.92% |
| Sofinnova Investments, Inc. | 658,249 | $16,963,000 | 1.29% |
| Perceptive Advisors | 1,845,555 | $47,560,000 | 0.95% |